Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market"

This is for your information.

For Dr. Reddy's Laboratories Limited

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Dr. Reddy's Laboratories announces the

launch of Bortezomib

for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

Hyderabad, India and Princeton, NJ,

USA. July 27, 2022 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with

its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Bortezomib for Injection

3.5 mg, the generic equivalent of Velcade (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration

The Velcade Brand and generic had

U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health*.

Dr. Reddy's Bortezomib for Injection,

is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.

Click here for full prescribing information:

Velcade is a trademark of Takeda Pharmaceuticals

*IQVIA Retail and Non-Retail MAT May 2022

About Dr. Reddy's: Dr. Reddy's

Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to

providing affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services

including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas

of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates

in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,

log on to: www.drreddys.com

Disclaimer: This press release may include

statements of future expectations and other forward-looking statements that are based on the management's current views and

assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ

materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of

context, the words "may", "will", "should", "expects", "plans", "intends",

"anticipates", "believes", "estimates", "predicts", "potential", or "continue"

and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those

in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit

defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality

and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and

regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including

related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers',

products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness,

including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities

and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections

of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information